Analysis
What changed: Pulse tracked the biotech IPO window reopening in late July as BlossomHill, Braveheart Bio and Attovia Therapeutics all set terms. That window has now closed out its strongest stretch since spring -- BlossomHill Therapeutics and Latigo Biotherapeutics both completed their upsized offerings by August 10, according to Seeking Alpha and Renaissance Capital's weekly recap.
BlossomHill, a San Diego clinical-stage cancer drug developer, priced 9,375,000 shares at $16.00 each for $150 million in gross proceeds. Latigo priced 19,200,000 shares at $18.00 for roughly $345.6 million, trading on Nasdaq under LTGO since August 7 with the offering formally closing August 10. Combined with Braveheart Bio's $383 million raise and Attovia's $289 million debut, four consecutive biotech IPOs targeted roughly $972 million in aggregate proceeds across a single ten-day window, according to IPOScoop.
“BlossomHill, a San Diego clinical-stage cancer drug developer, priced 9,375,000 shares at $16.00 each for $150 million in gross proceeds.”
The pattern across four deals closing in the same window is the more durable signal than any single company's terms: generalist and specialist biotech investors both appear to have real capital to deploy right now, not just enough for one marquee name before the pool runs dry. Every deal in the cluster priced at or above its original range, and none needed to cut size to get done.
The open question this window doesn't answer is whether the capital behind these four deals is broad enough to support the next wave of biotech filings still in registration, or whether it's concentrated among investors who've already deployed most of what they earmarked for this specific stretch of the year -- that will only become clear once the next cluster of biotech IPOs tries to price.